Received 11 May 1998/Returned for modification 6 July 1998/Accepted 17 July 1998
 |
INTRODUCTION |
Programmed cell death (PCD) or
apoptosis is a genetically controlled and evolutionarily conserved
mechanism of the cell to commit suicide. It is widely recognized that
apoptosis plays a critical role in organ development, tissue
homeostasis, and disease processes (24, 46). Inappropriate
regulation of apoptosis can lead to neurodegenerative disorders,
abnormal development, and cancer. Therefore, identifying and
understanding the mechanism of action of components of the apoptotic
machinery are fundamentally important in a variety of physiological
settings.
Genetic analysis of the nematode Caenorhabditis elegans has
identified three important components of the cell death pathway, which
are also conserved in vertebrates (14, 21). CED-3 is an
effector for inducing PCD and is a member of the family of aspartate-specific cysteine proteases known as caspases (20, 56). Another important component of cell death regulation
machinery in C. elegans is CED-4, which also induces PCD
(42, 54). Genetic studies have indicated that CED-4 requires
CED-3 to induce PCD and that CED-4 regulates the activity of CED-3,
suggesting that CED-4 may function upstream of CED-3 (42).
Recent biochemical and functional data have indicated that CED-4
induces the proteolytic activation of CED-3 (5, 41, 51),
indicating that CED-4 may function at a key regulatory step in the
process of PCD. A mammalian relative of CED-4, Apaf-1, which activates
caspase-9 in a cytochrome c- and dATP-dependent manner has
recently been identified (27, 57). A third component of the
C. elegans pathway is CED-9. However, CED-9 is an inhibitor
of apoptosis and blocks CED-3-induced cell death, which indicates that
it acts upstream of CED-3 (22). Furthermore, CED-4 is
required for the inhibition of CED-3-induced cell death by CED-9,
suggesting that CED-9 regulates CED-3 through CED-4 (41,
42). Mammalian counterparts of CED-9 are the antiapoptotic Bcl-2
family members which include Bcl-2, Bcl-xL, and the
adenoviral E1B 19,000-molecular-weight protein (E1B 19K) (26,
46). Bcl-2, Bcl-xL, and E1B 19K block the activation of caspases, which is consistent with the function of CED-9 in nematodes (2, 25, 32, 35, 37). Therefore, the basic PCD
machinery in both C. elegans and mammals includes effectors (caspases such as CED-3), activators (so far represented by CED-4 and
Apaf-1), and inhibitors (antiapoptotic Bcl-2 family members represented
by CED-9, Bcl-2, Bcl-xL, and E1B 19K) to regulate apoptosis. Precisely how these proteins accomplish this regulation at
the biochemical level has been emerging only recently.
In vitro, in Saccharomyces cerevisiae two-hybrid assays, and
in overexpression experiments with mammalian cells, CED-4 can interact
directly with CED-9 and CED-3 (6, 41, 44, 52). Furthermore,
CED-4 activates CED-3 processing and accelerates CED-3-induced
apoptosis (5, 41, 51). CED-9, in turn, prevents CED-4 from
activating CED-3, thereby inhibiting CED-3 processing (5, 41,
51). In mammalian cells, exogenously expressed CED-4 also
interacts with Bcl-xL and FLICE or ICE (6).
These data suggest that the function of these three main components of
the cell death machinery may be regulated by direct interaction and
that this mechanism is conserved between nematodes and mammals.
Bcl-2 family members play a critical role in the regulation of
apoptosis in a variety of different settings. Bcl-2-homologous proteins
are divided into two categories according to functional activity, i.e.,
antiapoptotic and proapoptotic proteins (26, 36), suggesting
that the regulation of apoptosis in mammals is more complex than in
C. elegans. A common feature of the regulation by Bcl-2
family members is homo- and heterodimerization between antiapoptotic
and proapoptotic proteins to either induce or inhibit apoptosis
(30). It has been demonstrated that Bcl-xL, an
antiapoptotic protein, interacts with CED-4 but that Bax and Nbk (also
called Bik), proapoptotic proteins, do not (6). It has been
proposed that Bcl-xL interacts with and inhibits the
function of CED-4, or perhaps mammalian counterparts of CED-4, and that
Bax and Nbk/Bik antagonize Bcl-xL but not CED-4, thereby
inducing cell death (6). Whether this simplistic model in
which the death regulators interact directly with each other is
sufficient to explain the mechanism of cell death control remains to be
determined.
The function of the adenoviral Bcl-2 homologue E1B 19K appears to be
very similar to that of other Bcl-2 family members. Bcl-2, for example,
will substitute for E1B 19K during adenovirus infection of human cells
and will cooperate with E1A to transform rodent cells (10, 33,
45). In addition, E1B 19K, Bcl-xL, and Bcl-2 have
sequence homology, particularly within Bcl-2-homologous regions 1 and 3 (3, 10, 12, 17, 53), and block apoptosis induced by p53
(9, 13, 38, 40). Bcl-2, Bcl-xL, and E1B 19K also bind to Bax, Nbk/Bik, and Bak (46). Therefore, E1B 19K shows functional and sequence homology with Bcl-2 and Bcl-xL and
interacts with some of the same cellular proteins, suggesting that
these Bcl-2 family members may act by similar mechanisms to inhibit apoptosis.
To extend the observations on the protein interactions between E1B 19K,
Bcl-2, and Bcl-xL, we tested E1B 19K for the ability to
bind to and regulate CED-4-dependent caspase activation. E1B 19K
interacted with CED-4 in a yeast two-hybrid assay, in vitro, and in
cell lysates. Subcellular localization of CED-4 was dramatically altered in E1B 19K-expressing cells and CED-4 was colocalized with E1B
19K. In functional assays, CED-4 alone did not induce cell death but
rather potentiated cell death induction by FLICE, which was inhibited
by E1B 19K expression. Thus, E1B 19K shares the ability of
Bcl-xL to bind to and inhibit CED-4-dependent FLICE activation and thereby apoptosis.
 |
MATERIALS AND METHODS |
Plasmid construction.
The standard PCR technique was used to
generate yeast fusion plasmids (pAS-CED-4, pGAD-19K, and pGBT9-ratBax).
The PCR product of CED-4 (51) was digested with
XmaI and PstI and ligated into the pAS vector.
E1B 19K was cloned into the pGAD vector by using EcoRI and
XhoI sites. Rat Bax (rBax) was cloned into pGBT9 by using
EcoRI and BamHI sites. Missense mutants of E1B
19K (pm7, pm44, pm51, pm87, and pm102) (10, 11, 50) were
cloned by PCR in pGAD at EcoRI and XhoI sites.
pACT-CED-9, pGAD-ratBax, and pGAD-hNbk were previously described
(16, 17, 52).
E1B 19K in pGEX4T-1 was previously described (16). All of
E1B 19K deletion mutants (mutants with deletions of N30 [
N30], C93, C70, and C36, and mutants containing amino acids 30 to 146, 30 to
93, and 64 to 146) were subcloned from the pGBT9 vector (34)
into the pGEX4T-1 vector by using EcoRI and SalI
sites. The BamHI site from the pGBT9 vector remained intact.
Human Bcl-2 in pGEX4T-3 was cloned by standard PCR methods by using
EcoRI and XhoI sites without the transmembrane
region of human Bcl-2 at the C terminus (deletion of 13 amino acids).
rBax in pGEX4T-1 was also cloned at EcoRI and
XhoI sites without the transmembrane region of rBax at the C
terminus (deletion of 19 amino acids).
pcDNA3-E1B 19K and pcDNA3-Myc-ratBax mammalian expression vectors were
previously described (16). pcDNA3-AU1-FADD (7) and pcDNA3-HA-FLICE (29) are cytomegalovirus (CMV)
expression vectors that express an N-terminal AU1-tagged human FADD and
a C-terminal hemagglutinin (HA)-tagged human FLICE, respectively. Both
expression vectors were generously provided by Vishva Dixit (University
of Michigan, Ann Arbor). pcDNA3-Flag-Bcl-xL (43) is a CMV-driven expression vector expressing the human
Bcl-xL protein with a Flag epitope tag at the N terminus.
Wild-type CED-4 and mutant CED-4 proteins (those with the mutations
N86,
C473,
C328,
C401, I258N, and DD250-251AA) were cloned
into pcDNA3 at a KpnI site and have a Myc tag at their N
termini (52). E1B 19K mutant CMV expression vectors (pm7,
pm44, pm51, pm87, and pm102) were previously described (10, 11,
50).
Two-hybrid system.
Binding ability for each combination of
interacting proteins was analyzed with the YGH1 strain (ura3-25
his3-200 ade2-101 lys-2,801 trp1-901 leu2-3
Canr gal4-542 gal80-538
LYS2::gal1uas-gal1tata-HIS3
URA3::gal1-lacZ) (18).
Transformations were performed by standard lithium acetate procedures,
with 4 µg of plasmid DNA and 20 µg of sheared, denatured salmon
sperm DNA being used for each transformation. Transformants were plated
on yeast dropout plates lacking leucine and tryptophan. Transformants
were assayed for
-galactosidase activity by a filter-based assay
(18).
Protein interaction assays.
For fusion protein binding
assays, BL21 DE3 was transformed with the glutathione
S-transferase (GST) fusion plasmids indicated in the
figures, and expression was induced with 0.5 mM
isopropyl-
-D-thiogalactopyranoside. A 100-µl aliquot
of culture was analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) to evaluate fusion protein induction. The
remaining culture was sonicated on ice by using seven short bursts at
10 s each (Fischer Sonic Dismembranator 3000) and clarified by
centrifugation, and the supernatant was resuspended in 50% (vol/vol)
glutathione-Sepharose beads (Pharmacia Biotech, Piscataway, N. J.). An aliquot of the protein-bound beads was analyzed by SDS-PAGE to
ensure that equal amounts of pure fusion proteins were present.
In vitro binding assays for CED-4 and E1B 19K interaction were
performed by incubating equal amounts of GST or GST-E1B 19K fusion
protein (immobilized on glutathione-Sepharose beads) with in
vitro-translated CED-4 protein diluted in 0.5 ml of buffer (50 mM Tris
[pH 7.5], 150 mM NaCl, 0.2% Nonidet P-40 [NP-40]). The mixture was
incubated for 2 h at 4°C, washed three times with buffer, and
resuspended in 2× Laemmli buffer. All samples were boiled for 5 min,
and proteins were resolved by SDS-12% PAGE. Gels were fixed in 50%
methanol and 10% glacial acetic acid for 2 h and dried.
To detect the interaction of E1B 19K and CED-4 in cell lysates,
pcDNA3-Myc-CED-4 was transfected into COS cells. Twenty-four hours
posttransfection the transfected cells were washed with phosphate-buffered saline and lysed in 1 ml of cold NETN lysis buffer
(20 mM Tris [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.2% NP-40) containing
protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10 mM
benzamidine, 0.1 mg of bacitracin per ml, 1.0 µg of pepstatin A per
ml, 10 mM sodium bisulfite) for 20 min. The cell lysate was centrifuged
at 10,000 × g for 10 min to remove cellular debris. The lysate was then incubated with GST alone and GST-19K bound to
glutathione-Sepharose beads for 2 h and washed as described above.
Samples were resolved by SDS-17% PAGE. The precipitated CED-4 protein
was detected by Western blot analysis with an anti-Myc monoclonal
antibody (Oncogene Science, Inc., Cambridge, Mass.).
All mutant CED-4 proteins were tested for binding to E1B 19K and the
protein with amino acids 64 to 146 by the GST system. Equal amounts of
GST, GST-19K, and the protein with amino acids 64 to 146 (3 µg) were
incubated with in vitro-transcribed mutant CED-4 proteins (with the
mutations
N86,
C473,
C328,
C401, I258N, and DD250-251AA)
diluted in 0.5 ml of the NETN buffer. The mixtures were incubated for
2 h and washed. Samples were resolved by SDS-12% PAGE.
The E1B 19K deletion mutant proteins (the proteins with the mutations
N30,
C93,
C70, and
C36 and the proteins with amino acids 30 to 146, 30 to 93, and 64 to 146) in pGEX4T-1 were used in a binding
assay to determine their abilities to bind to rBax and CED-4. In
vitro-translated rBax or CED-4 was incubated with an equal amount of
each E1B 19K deletion mutant protein and immobilized on
glutathione-Sepharose beads in 0.5 ml of the NETN buffer. After 2 h of incubation, the mixtures were washed and resolved by SDS-20% PAGE.
rBax antagonization of the E1B 19K and CED-4 interaction was performed
with GST-19K, GST-Bax, GST-Bcl-2, and in vitro-translated CED-4.
GST-Bax and GST-Bcl-2 proteins in the amounts 2.5, 5, and 7.5 µg were
added to 2.5-µg amounts of GST-19K and in vitro-translated CED-4 in
the binding assay. These mixtures were incubated in 0.5 ml of the NETN
buffer for 2 h and washed with the same buffer. The precipitates
were resolved by SDS-20% PAGE.
Indirect immunofluorescence.
COS cells were electroporated
with the pcDNA3-Myc-CED-4 and pcDNA3-19K. Cells were fixed with
methanol 24 h posttransfection and double-labeled with an anti-Myc
monoclonal antibody (Oncogene Science, Inc.) at a 1:5 dilution and an
anti-E1B 19K polyclonal antibody (p21) (49) at a 1:200
dilution. Antibodies were visualized with goat anti-mouse
rhodamine-conjugated and goat anti-rabbit fluorescein-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West
Grove, Pa.).
Functional assays.
To examine CED-4 and E1B 19K functional
relationships in transient-expression assays, 6 µg of
pcDNA3-Myc-CED-4 and 2 µg of pCMV
-gal carrying the gene expressing
-galactosidase from the CMV promoter were cotransfected with 18 µg
of pcDNA3-19K or pcDNA3-Flag-Bcl-xL into HeLa cells by
electroporation as previously described (9). The amount of
transfected DNA from the pcDNA3-AU1-FADD and pcDNA3-HA-FLICE plasmids
was also fixed at 6 µg. The transfected cells were incubated for
24 h and 72 h. Percentages of blue cells were assessed as described previously (17).
CED-4 mutant proteins (the
N86,
C473,
C328,
C401, I258N,
and DD250-251AA proteins) were used to define the regulatory region of
CED-4 for augmenting FLICE-induced apoptosis. Six micrograms of CED-4,
6 µg of CED-4 mutant proteins, 6 µg of FLICE, and 18 µg of E1B
19K were used for transfection into HeLa cells. For each combination, 2 µg of the pCMV
-gal construct was included. The combined DNA was
transfected into HeLa cells and incubated for 24 h. Percentages of
blue cells were assessed as described previously (17).
Missense E1B 19K mutant proteins (pm7, pm44, pm51, pm87, and pm102)
were assayed for inhibition of rBax-induced apoptosis and
CED-4-dependent, FLICE-mediated apoptosis. Eighteen micrograms of
pcDNA3-19K was cotransfected with 6 µg of pcDNA3-rBax or with 6 µg
of pcDNA3-Myc-CED-4 and 6 µg of pcDNA3-HA-FLICE into HeLa cells. Two
micrograms of the pCMV
-gal construct was also included. The
transfected cells were incubated for 24 h, and the percentages of
blue cells were assessed as described previously (17).
Western blotting.
Cell extracts for Western blot analysis
were prepared from subconfluent cultures, and 25 µg of protein from
each cell line was analyzed by SDS-PAGE and semidry blotting onto
nitrocellulose membranes by standard procedures. Immune complexes were
detected by enhanced chemiluminescence according to the specifications of the manufacturer (Amersham Corp., Arlington Heights, Ill.).
To check the expression of CED-4 mutant proteins, all CED-4 mutant
constructs were transfected into COS cells and 24 h
posttransfection the expression of CED-4 mutant proteins was detected
by Western blot analysis with an anti-Myc monoclonal antibody (Oncogene
Science, Inc.).
 |
RESULTS |
E1B 19K interacts with CED-4 in yeast.
To determine the
ability of E1B 19K to bind to CED-4, yeast two-hybrid assays were
performed. The CED-4 cDNA was cloned in frame with the yeast GAL4
DNA-binding domain of the pAS vector. E1B 19K was fused to the GAL4
activation domain in the pGAD vector as previously described
(16). The binding activity was assessed by an X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) filter
assay. CED-4 interacted with E1B 19K, although it showed less binding
ability than CED-9 with CED-4 (Table 1).
The association of CED-4 with E1B 19K was specific in that CED-4 was
unable to interact with the other Bcl-2 family members, Bax, and
Nbk/Bik (Table 1). These results suggest that E1B 19K, as well as
CED-9, interacts specifically with CED-4. Since proapoptotic Bcl-2
homologues such as Bax and Nbk/Bik do not interact with CED-4, they may
function by interacting with and inhibiting antiapoptotic Bcl-2-like
proteins and preventing their association.
E1B 19K associates with CED-4 in vitro and in cell lysates.
A
GST fusion protein system was employed to confirm the binding
specificity of CED-4 with E1B 19K in yeast. GST alone and GST-19K
fusion proteins were immobilized on glutathione-Sepharose beads and
purified. Equal amounts of GST fusion proteins (3 µg) were mixed with
in vitro-transcribed and -translated and
[35S]methionine-labeled CED-4 in buffer containing 0.2%
NP-40. In vitro-translated CED-4 bound to GST-19K fusion protein, but
it did not interact with GST alone (Fig.
1A). These results indicate that E1B 19K
can specifically interact with CED-4 in vitro, which serves as an
independent confirmation of results obtained from the yeast two-hybrid
system.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Interaction of E1B 19K with CED-4 in vitro and in cell
lysates. (A) In vitro-translated CED-4 associates with the GST-19K
fusion protein. GST fusion proteins were immobilized on
glutathione-Sepharose beads and incubated with in vitro-translated
CED-4 protein in a buffer containing 0.2% NP-40. The first lane in
panel A shows in vitro-translated CED-4 protein. (B) Interaction of the
cellular CED-4 protein with GST-19K. pcDNA3-Myc-CED-4 was transfected
into COS cells, and cold cell lysates prepared from the transfected
cells were incubated with GST fusion proteins. The precipitated
proteins from the GST fusion proteins were analyzed by SDS-PAGE and by
Western blotting with an anti-Myc monoclonal antibody against a Myc tag
on CED-4.
|
|
To substantiate the physiological relevance of the CED-4 and E1B 19K
interaction, the interaction in mammalian cells was assessed. The E1B
19K protein, however, is insoluble in mammalian cells, necessitating
harsh detergent conditions to extract the E1B 19K protein for
immunoprecipitation (47, 48). In order to circumvent this
problem, the E1B 19K protein was immobilized on glutathione-Sepharose beads as a GST fusion protein (GST-19K) and then incubated with unlabeled lysates prepared from CED-4-transfected COS cells. Cellular proteins bound to the GST-19K fusion protein were analyzed by an
immunoblotting assay with an anti-Myc monoclonal antibody directed against a Myc epitope tag on CED-4. CED-4 was specifically detected only when it was incubated with GST-19K fusion protein and not with GST
alone (Fig. 1B). These results demonstrate that E1B 19K can associate
with CED-4 specifically in the context of a whole-cell extract,
supporting the findings obtained from the two-hybrid system and the in
vitro binding assays.
E1B 19K alters the subcellular localization of CED-4.
To
assess the subcellular localization of CED-4 in the absence and in the
presence of E1B 19K protein, double-label indirect immunofluorescence experiments were performed. The CED-4
expression vector (pcDNA3-Myc-CED-4) was transfected with or without
the E1B 19K expression vector (pcDNA3-E1B 19K) into COS cells, and the
cells were fixed at 24 h posttransfection and stained with a
monoclonal antibody specific for the Myc epitope on CED-4 and a
polyclonal antibody directed against the E1B 19K protein. CED-4 displayed a diffuse, cytoplasmic localization pattern, indicating that
it was localized in the cytosol as previously described (52) (Fig. 2A). As previously reported, the E1B 19K protein is associated with the cytoplasmic and nuclear membranes and with the insoluble nuclear lamina (34, 47, 48). Coexpression of CED-4 and E1B 19K resulted in a dramatic change of the localization of CED-4 (Fig.
2B). The CED-4 protein was relocalized to
perinuclear membranes at locations corresponding to the intracellular
distribution of the E1B 19K protein (Fig. 2C). Approximately 85% of
the CED-4- and E1B 19K-expressing cells displayed this colocalization
pattern, indicating that E1B 19K expression altered the subcellular
localization of CED-4.

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 2.
Subcellular localization patterns of CED-4 in the
presence and absence of E1B 19K. COS cells were transfected with
pcDNA3-Myc-CED-4 and/or pcDNA3-19K expression vectors and processed for
double-label indirect immunofluorescence 24 h posttransfection.
The cells were stained with an anti-Myc monoclonal antibody against a
Myc tag on CED-4 and an anti-E1B 19K polyclonal antibody directed
against the E1B 19K protein (p21 antibody). (A) CED-4 expression alone.
The transfected cells were stained with an anti-Myc monoclonal
antibody. (B and C) Coexpression of CED-4 and E1B 19K. (B) An anti-Myc
monoclonal antibody against a Myc tag on CED-4 was used to stain the
transfected cells. (C) An anti-19K polyclonal antibody directed against
the E1B 19K protein was used for staining.
|
|
E1B 19K inhibits CED-4-dependent, FLICE-mediated apoptosis.
The E1B 19K protein blocks Fas and tumor necrosis factor alpha pathways
(15, 19, 50), where an adaptor molecule, FADD, recruits
FLICE to the death receptor complex to induce apoptosis (1,
8). FADD-induced apoptosis can be blocked by E1B 19K, whereas
FLICE-induced apoptosis cannot (32) (Fig.
3). However, when FADD and FLICE are
coexpressed, E1B 19K inhibits FADD-dependent FLICE activation and cell
death (32) (Fig. 3). This demonstrates that E1B 19K is able
to block FLICE-induced apoptosis in the presence of FADD. The mechanism
by which E1B 19K blocks FLICE-induced cell death through FADD may be
functionally analogous to the C. elegans model system for
regulating apoptosis. Through a direct interaction of E1B 19K with
CED-4, it is conceivable that E1B 19K may block FLICE-induced apoptosis
through CED-4, which parallels the inhibition of FADD-mediated FLICE
activation by E1B 19K. Thus, we sought to determine if E1B 19K could
regulate CED-4-dependent FLICE-mediated apoptosis in similar assays.

View larger version (42K):
[in this window]
[in a new window]

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
E1B 19K inhibits the ability of CED-4 to potentiate
FLICE-induced apoptosis. The pcDNA3-Myc-CED-4, pcDNA3-AU1-FADD, and
pcDNA3-HA-FLICE constructs were cotransfected by electroporation with
pcDNA3-19K or pcDNA3-Flag-Bcl-xL into HeLa cells as
indicated. pCMV -gal was included for each combination of
transfection. The percentage of blue viable cells in each combination
was determined relative to that in the vector control (Vec). At 24 (A)
and 72 (B) h posttransfection, a -galactosidase assay was
performed.
|
|
To examine a functional relationship between CED-4 and E1B 19K, HeLa
cells were transiently transfected with CED-4, FLICE, FADD, and E1B 19K
expression vectors. The transfection of CED-4 into HeLa cells did not
induce cell death (41, 52) (Fig. 3). In support of this
observation, a genetic study of C. elegans has suggested
that CED-4 requires CED-3 to implement cell death (42). To
investigate the function of CED-4 in the presence of FLICE, a mammalian
counterpart of CED-3, CED-4 and FLICE expression vectors were
cotransfected with pCMV
-gal to express
-galactosidase in HeLa
cells, and the percentages of blue viable cells were assessed at 24 and
72 h posttransfection.
FADD expression induced cell death at 24 h posttransfection, but
E1B 19K or Bcl-xL blocked FADD-induced apoptosis (Fig. 3) (32). FLICE expression alone did not induce substantial cell death at 24 h posttransfection but did so dramatically at 72 h posttransfection. Thus, FLICE expression was not inhibited by E1B 19K
or Bcl-xL (Fig. 3). E1B 19K or Bcl-xL, however,
blocked FLICE-induced apoptosis when FLICE was coexpressed with FADD
(Fig. 3) (32). Although CED-4 alone did not induce cell
death, coexpression of CED-4 and FLICE strongly induced cell death
compared to that induced by FLICE alone at 24 h posttransfection
(Fig. 3), indicating that CED-4 stimulates the ability of FLICE to
induce cell death in mammalian cells. Importantly, the cotransfection
of E1B 19K or Bcl-xL with CED-4 and FLICE blocked
CED-4-dependent, FLICE-mediated apoptosis (Fig. 3), indicating that
CED-4 is required for E1B 19K or Bcl-xL to inhibit
FLICE-induced apoptosis. Thus, CED-4 alone cannot induce cell death but
CED-4 potentiates FLICE-induced apoptosis. However, E1B 19K or
Bcl-xL inhibits CED-4-dependent, FLICE-mediated apoptosis
and CED-4 is necessary for E1B 19K or Bcl-xL to block
FLICE-induced apoptosis. These results remarkably parallel the
requirement of FADD for E1B 19K to inhibit FLICE activation and
apoptosis (32).
Mutational analysis of CED-4 binding and function.
To
determine the binding specificity of CED-4 for E1B 19K, we used a
series of mutant forms of CED-4 in GST fusion protein binding assays.
The
C328,
C401, and I258N proteins are three CED-4 mutant
proteins that display a loss-of-function phenotype in C. elegans (Fig. 4A) (55).
The
C328 and
C401 proteins have stop codons at residues 328 and
401, respectively (Fig. 4A). The I258N protein has an amino acid
substitution of Asn for Ile at residue 258 (Fig. 4A). We also generated
three other CED-4 mutant proteins, the
N86,
C473, and DD250-1AA
proteins (Fig. 4A). The
N86 protein has the first 86 N-terminal
amino acids deleted and thus does not contain the caspase recruitment
domain (CARD). The
C473 protein contains a stop codon at position
473 but retains the CARD and the Apaf-1-homologous region
(57). The DD250-251AA protein introduces two point mutations
of Asp to Ala at residues of 250 and 251 in the second P-loop site
(57) (Fig. 4A).

View larger version (21K):
[in this window]
[in a new window]

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Mapping of the E1B 19K binding region in CED-4. (A)
Schematic representation of CED-4 and corresponding mutant proteins.
P-loops represent locations of predicted ATP-binding sites. Amino acids
1 to 88 have CARD homology. Amino acids 89 to 435 are homologous to
part of Apaf-1, which is a mammalian homologue of CED-4. (B) Binding of
the CED-4 mutant proteins to E1B 19K. GST fusion proteins, GST alone,
and GST-19K were immobilized on glutathione-Sepharose beads and were
incubated with each in vitro-translated wild-type and CED-4 mutant
protein in the buffer containing 0.2% NP-40. The mixtures were
incubated for 2 h and washed three times with the NETN buffer.
Samples were resolved by SDS-12% PAGE.
|
|
For binding assays with GST fusion proteins, GST alone or GST-19K was
incubated for 2 h with each in vitro-translated CED-4 mutant
protein in buffer containing 0.2% NP-40. Unlike GST alone, the GST-19K
fusion protein precipitated wild-type CED-4 (Fig. 4B). All of the CED-4
mutant proteins also interacted with GST-19K, but not with GST alone,
although the
N86 and DD250-251AA proteins displayed dramatically
reduced binding abilities (Fig. 4B). It has been reported that the
C328,
C401, and I258N mutant proteins also interact with CED-9
(51) as they did with E1B 19K (Fig. 4). These results
suggest that there may be two binding sites in CED-4 for E1B 19K, one
located in the CARD and the other located between residues 87 and 327 in CED-4 in the region homologous to Apaf-1. Since FADD has a death
effector domain (DED) which is structurally related to the CARD, the
requirement of the CARD of CED-4 for efficient E1B 19K binding may be
related.
CED-4 mutant proteins were then evaluated for functional activity in
mammalian cells (Fig. 5). All CED-4
constructs were transfected into COS cells, and at 24 h
posttransfection, the expression of the proteins was detected by
conventional Western blot analysis with an anti-Myc monoclonal
antibody. With the exception of the
N86 protein, all CED-4 mutant
proteins were highly expressed, at levels comparable to the level of
expression of wild-type CED-4 (Fig. 5A).

View larger version (51K):
[in this window]
[in a new window]

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Functional analysis of CED-4 mutant proteins and
inhibition by E1B 19K. (A) Expression levels of CED-4 mutant proteins.
Each CED-4 mutant construct was transfected into COS cells, and 24 h posttransfection the levels of expression of wild-type and mutant
CED-4 proteins were detected by Western blot analysis with an anti-Myc
monoclonal antibody directed against the epitope tag. (B) Abilities of
wild-type and CED-4 mutant proteins to activate FLICE-induced
apoptosis. Wild-type CED-4, CED-4 mutant protein (with mutations
N86, C473, C328, C401, I258N, and DD250-251AA), FLICE,
and/or E1B 19K expression vectors were cotransfected with pCMV -gal
into HeLa cells as indicated in the figure. The transfected cells were
incubated for 24 h. The percentage of blue viable cells in each
transfection was determined relative to that in the vector control
(Vec). , no CED-4 or CED-4 mutant DNA added.
|
|
Wild-type CED-4 does not induce cell death by itself (51)
but rather augments FLICE-induced apoptosis (Fig. 3). To characterize the ability of mutant forms of CED-4 to stimulate FLICE-induced apoptosis, each CED-4 mutant expression vector was cotransfected with
the FLICE and pCMV
-gal vectors into HeLa cells. The percentages of
blue cells were assessed by a
-galactosidase assay 24 h
posttransfection. Wild-type CED-4 displayed potent killing activity
only in the presence of FLICE, as was indicated by the low percentage
of blue cells (Fig. 5B). The
N86,
C328,
C401, I258N, and
DD250-251AA CED-4 mutant proteins were defective in their ability to
augment FLICE-induced apoptosis (Fig. 5B). It has been shown that the CED-4
C328,
C401, and I258N mutant proteins display a
loss-of-function phenotype in C. elegans (55),
which is consistent with the results with HeLa cells. The
C473
protein, however, retained FLICE-dependent cell killing activity (Fig.
5B). Since E1B 19K interacted with the
C473 protein, it is not
surprising that E1B 19K inhibited the apoptotic effect of the
C473
protein (Fig. 5B). Therefore, only the C-terminal 77 amino acids may be
dispensable for stimulating FLICE-induced apoptosis.
Mutational analysis of E1B 19K binding and function.
It has
been demonstrated that E1B 19K interacts with Bax and inhibits
Bax-induced apoptosis (4, 16). In this report, it has been
shown that E1B 19K also binds to CED-4 and blocks CED-4-dependent,
FLICE-mediated apoptosis. We performed a GST fusion protein binding
assay using deletion mutant proteins of E1B 19K to map the sequence
requirement in E1B 19K for interaction with CED-4 and Bax (Fig.
6). Wild-type E1B 19K interacted with both Bax and CED-4, whereas GST alone did not bind to either Bax or
CED-4 (Fig. 6B). The E1B 19K protein has a moderately conserved N
terminus which includes BH3, a highly conserved central region which
includes BH1, and a poorly conserved C terminus (10, 50). Deletion of the E1B 19K N terminus in proximity to BH3 ablated Bax
binding but not binding to CED-4 (Fig. 6A and B). Deletion of the
C-terminal half (or more) of E1B 19K did not permit binding to either
CED-4 or Bax (Fig. 6A and B). Whether this deletion caused the E1B 19K
protein to be misfolded is not known. However, smaller E1B 19K
fragments containing only BH3 (the
C70 protein and the protein with
amino acids 19 to 57) bound both CED-4 and Bax, suggesting that BH3 is
a binding site on E1B 19K for both (Fig. 6A and B). Whereas BH3
appeared to be the only sequence determinant on E1B 19K required for
Bax interaction, an E1B 19K mutant protein (the protein containing
amino acids 64 to 146) which lacked BH3 but contained the central
conserved region including BH1 interacted with CED-4 more robustly than
full-length E1B 19K (Fig. 6A and B). Thus, BH3 serves as the only E1B
19K binding site for Bax whereas CED-4 interacts independently with two
regions of E1B 19K: BH3 and the central conserved region.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Mapping of the sequence determinants within E1B 19K
required for interaction with Bax and CED-4. (A) A schematic
representation of the E1B 19K protein and deletion mutants. Among the
various adenovirus serotypes, amino acids 1 to 81 have 44% identity,
amino acids 82 to 115 make up the most conserved region with 58%
identity, and amino acids 116 to 176 make up the least conserved region
with 22% identity (10). Brackets indicate BH1 and BH3. The
N30 protein is deleted from the amino-terminal direction. The
C93, C70, and C36 proteins are deleted from the
carboxy-terminal direction. The proteins with amino acids 30 to 146, 30 to 93, 64 to 146, and 19 to 57 are deleted from both directions.
Wild-type E1B 19K and deletion mutants were tested for interaction with
Bax and CED-4 in a GST fusion protein binding assay. +++++, very strong
interaction; +++, strong interaction; ++, moderate interaction; , no
interaction. (B) GST fusion protein binding assay of deletion mutants
of E1B 19K binding to Bax and CED-4. In vitro-translated rBax or CED-4
was incubated with the same amount of each E1B 19K deletion mutant and
immobilized on glutathione-Sepharose beads in 0.5 ml of the NETN
buffer. After 2 h of incubation, the mixtures were washed and
resolved by SDS-20% PAGE. (C) The E1B 19K deletion mutant with amino
acids 64 to 146 interacts with all CED-4 mutants. Equal amounts of GST
and GST plus the deletion mutant protein with amino acids 64 to 146 were incubated with each in vitro-translated CED-4 mutant in the NETN
buffer for 2 h. The mixtures were washed and resolved by SDS-12%
PAGE. WT, wild type.
|
|
As the E1B 19K mutant protein containing amino acids 64 to 146 interacted with CED-4 more strongly than the wild-type E1B 19K protein,
we tested its ability to bind to a series of CED-4 mutants to map the
region of CED-4 to which it bound (Fig. 6C). The mutant protein
containing amino acids 64 to 146 strongly interacted with wild-type
CED-4 and all CED-4 mutant proteins (Fig. 6C). These data indicate that
the binding site of the mutant protein containing amino acids 64 to 146 in CED-4 is also located from amino acids 87 to 327 of CED-4.
Interestingly, no diminution in binding to the
N86 protein was
observed with the protein with amino acids 64 to 146 (Fig. 6C), which
was observed with the wild-type E1B 19K protein (Fig. 6B). Perhaps BH3
of E1B 19K interacts with the N-terminal CARD of CED-4 and destabilizes
E1B 19K binding to CED-4.
Five previously characterized missense mutant proteins of the E1B 19K
protein (pm7, pm44, pm51, pm87, and pm102) were also used to define the
genetic requirements within E1B 19K for binding to CED-4 and Bax and
for inhibition of Bax and CED-4-dependent, FLICE-mediated apoptosis.
Functional experiments with the E1B 19K deletion mutant proteins named
above are not possible because they do not produce stable proteins. The
two-hybrid system was used to determine the abilities of the five 19K
missense mutant proteins to bind to Bax or CED-4. pm7, pm44, and pm102
maintained the ability to interact with Bax as previously reported
(16) (Fig. 7A). However,
substitution of either phenylalanine for serine at position 51 (pm51)
or glycine for alanine at position 87 (pm87) in the E1B 19K protein
resulted in loss of the ability to interact with Bax in yeast (10,
16) (Fig. 7A). Loss of Bax binding with pm51 is consistent with
the role of BH3 in the E1B 19K interaction with Bax. pm87 has an
alanine substitution in the glycine residue, which is conserved in the
BH1 of all Bcl-2 family members. This glycine residue is in a pivotal
location adjacent to the hydrophobic cleft which serves as the BH3
binding pocket and may thereby affect Bax binding (28, 39).
Wild-type CED-4 interacted with E1B 19K, whereas pm7, pm44, pm87, and
pm102 interacted weakly and pm51 did not interact with CED-4 (Fig. 7A).
These results support the findings with the deletion mutant proteins,
suggesting that CED-4 has two binding sites on E1B 19K but that Bax
requires only BH3. This is, again, exemplified by binding of pm87 to
CED-4 but not to Bax. Thus, there may be two binding sites on CED-4 for E1B 19K (CARD and amino acids 87 to 327) and two binding sites on E1B
19K for CED-4 (BH3 and amino acids 64 to 146, including BH1).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 7.
Mapping of E1B 19K binding to and inhibition of CED-4
and Bax. (A) Schematic representation of E1B 19K protein, locations of
missense mutations, and binding abilities of missense E1B 19K mutant
proteins to CED-4 and Bax. Wild-type and missense mutant proteins of
E1B 19K (pm7, pm44, pm51, pm87, and pm102) in the pGAD vector, Bax in
pGBT9, and CED-4 in pAS were used in yeast two-hybrid assays to detect
interaction. Each combination of plasmid expressing the GAL4
DNA-binding domain (pAS and pGBT9) and the GAL4 activation domain
(pGAD) was cotransformed into the YGH1 yeast strain as indicated. The
binding strength was assessed by an X-Gal assay. Strong interaction is
indicated by +++, moderate interaction is indicated by ++, weak
interaction is indicated by +, and no interaction is indicated by .
(B) Functional assay for E1B 19K inhibition of CED-4- and Bax-induced
apoptosis. Mutant proteins of E1B 19K were cotransfected with
pcDNA3-Myc-ratBax or pcDNA3-Myc-CED-4 and pcDNA3-HA-FLICE into HeLa
cells as indicated. For each combination, 2 µg of the pCMV -gal
plasmid was also cotransfected. Twenty-four hours posttransfection,
viability of cells was assessed by a -galactosidase assay. The
percentage of blue cells in the each transfection was determined
relative to that in the vector control. , no E1B 19K OR E1B 19K
mutant DNA added.
|
|
To evaluate the functional activity of the E1B 19K missense mutant
proteins, HeLa cells were cotransfected with Bax or CED-4 and FLICE
expression vectors (Fig. 7B). Twenty-four hours posttransfection, the
percentages of blue viable cells were assessed by a
-galactosidase assay. Expression levels of E1B 19K mutant proteins in HeLa cells were
measured by Western blot analysis (data not shown) and, as previously
reported, were similar to that of wild-type E1B 19K (10).
Wild-type E1B 19K showed antiapoptotic activity by efficiently blocking
both Bax-induced and CED-4 dependent, FLICE-mediated apoptosis, as was
indicated by the high percentage of blue cells (Fig. 7B). pm7 and pm44
displayed a reduced ability to block Bax-induced apoptosis but retained
the ability to inhibit CED-4-dependent, FLICE-mediated apoptosis (Fig.
7B). However, pm51 did not retain any survival-promoting function for
either Bax or CED-4-FLICE pathways (Fig. 7B). Alternatively, pm87
could not block apoptosis by Bax but retained most of its ability to
inhibit apoptosis by CED-4 and FLICE (Fig. 7B). Since pm87 binds to
CED-4 but not to Bax, E1B 19K binding appears to correlate with E1B 19K
function. pm102 retained the same level of antiapoptotic activity as
wild-type E1B 19K for both CED-4 and Bax (Fig. 7B). Thus, the pm87
mutation, which alters the absolutely conserved glycine residue in BH1, discriminates between CED-4 and Bax binding, suggesting that the E1B
19K protein binds to Bax and CED-4 differently. These different binding
profiles directly correlate with the ability of the E1B 19K protein to
inhibit Bax- and CED-4-dependent apoptosis (Fig. 7B).
Bax disrupts the interaction between E1B 19K and CED-4.
Since
the requirements within E1B 19K for interaction with Bax and CED-4
overlapped within BH3, we tested the ability of Bax to antagonize the
interaction of E1B 19K with CED-4 (Fig.
8). GST-19K and in vitro-translated CED-4
were used in a GST fusion protein binding assay with or without GST-Bax
or GST-Bcl-2. GST-19K precipitated with CED-4, although GST alone did
not (Fig. 8). Given that Bcl-2 does not interact with E1B 19K and
CED-4, addition of GST-Bcl-2 protein in the GST-19K and CED-4 binding
assay did not change the binding ability of E1B 19K to CED-4 (Fig. 8).
However, as the amount of GST-Bax protein was increased, the binding
ability of E1B 19K to CED-4 was decreased (Fig. 8). This result
indicates that Bax and CED-4 cannot interact with E1B 19K at the same
time. Therefore, Bax can antagonize the interaction of E1B 19K with CED-4. By preventing E1B 19K from interacting with CED-4, Bax may
promote caspase activation and thereby apoptosis.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 8.
Bax disrupts the interaction between CED-4 and E1B 19K.
GST-Bax or GST-Bcl-2 in the amounts 2.5, 5, and 7.5 µg was used in
binding assays with GST-19K (2.5 µg) and in vitro-translated CED-4.
These mixtures were incubated in the NETN buffer for 2 h and
washed with the same buffer. The precipitates were resolved by
SDS-20% PAGE.
|
|
E1B 19K inhibits FLICE processing.
We have shown that E1B 19K
blocks CED-4- and FLICE-induced apoptosis (Fig. 3). To address whether
E1B 19K blocks FLICE processing, HeLa cells were transiently
transfected with FLICE or FLICE plus CED-4 in the presence or absence
of E1B 19K (Fig. 9). Whole-cell extracts
were produced 24 h posttransfection and immunoblotted with an
anti-HA polyclonal antibody to detect the epitope on the FLICE N
terminus. The transfection of the pcDNA3 negative control vector and
CED-4 could not produce processed FLICE (Fig. 9). Since overexpression
of FLICE alone did not induce efficient cell death at 24 h
posttransfection, the inactive zymogen form of FLICE was still
detectable (Fig. 9). However, full-length FLICE disappeared when FLICE
was cotransfected with CED-4, indicating that CED-4 activated FLICE
processing (Fig. 9). Coexpression of E1B 19K with FLICE and CED-4
inhibited FLICE processing, as was indicated by the abundance of
unprocessed full-length FLICE (Fig. 9). Therefore, CED-4 activates
FLICE processing and E1B 19K blocks FLICE activation through CED-4,
which is consistent with inhibition of CED-4-dependent, FLICE-mediated
apoptosis by E1B 19K.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 9.
E1B 19K blocks FLICE activation. HeLa cells were
transfected with the pcDNA3 control vector, FLICE, and CED-4 plus FLICE
in the presence or absence of E1B 19K at the same concentrations used
in the viability assay (Fig. 3). Twenty-four hours posttransfection,
whole-cell lysates were prepared, resolved by SDS-PAGE, and then
immunoblotted with an anti-HA polyclonal antibody to recognize
pro-FLICE (66 kDa).
|
|
 |
DISCUSSION |
We have demonstrated that CED-4 interacts with the E1B 19K protein
but not with either Bax or Nbk/Bik. E1B 19K expression altered the
cytosolic localization of CED-4 to that of its own perinuclear membrane
localization pattern. CED-4 expression alone did not induce cell death,
but CED-4 stimulated the killing effect of FLICE, suggesting that CED-4
activates FLICE. E1B 19K blocked this CED-4-dependent, FLICE-mediated
apoptosis, and this E1B 19K inhibition of CED-4 cosegregated with the
ability of E1B 19K to bind to CED-4. Thus, E1B 19K most likely
interacts with a mammalian homologue of CED-4 to prevent caspase
activation and apoptosis, as Bcl-xL binds to Apaf-1 and
inhibits caspase-9 activation (23, 31). These observations
are reminiscent of inhibition of FADD-dependent FLICE activation by E1B
19K (32). The E1B 19K protein may prevent caspase activation
and thereby apoptosis generally by inhibiting activators (CED-4) or
adapters (FADD).
Recently published data have shown that CED-4 alone induces cell death
(6, 31). However, expression of CED-4 alone did not induce
cell death in our experiments. Genetic analysis has also shown that
CED-4 requires CED-3 to induce cell death (42). In support
of this observation, several other groups have recently reported that
CED-4 alone does not induce cell death in 293T cells, MCF-7 breast
carcinoma cells, and Sf-21 cells (41, 51). The discrepancy
in CED-4 activities may result from the use of different cell lines and
methods used for transfection.
Mutation analysis of both E1B 19K and CED-4 has indicated that there
are two interaction regions on E1B 19K for CED-4 (BH3 and amino acids
64 to 146) as well as two interaction regions on CED-4 for E1B 19K
(CARD and amino acids 87 to 327) (Fig.
10). Amino acids 87 to 327 make up the
region of CED-4 which is homologous to Apaf-1 (Fig. 4). Whether E1B 19K
also interacts with and inhibits caspase activation by Apaf-1 remains
to be determined. Removal of the CARD of CED-4 (
N86) greatly
diminished interaction with E1B 19K (Fig. 6B), suggesting that the CARD
is one binding site for E1B 19K. Interestingly, FADD contains a DED
that is a specific type of CARD (1, 29). E1B 19K efficiently
blocks FADD-dependent FLICE activation (32), which
remarkably parallels E1B 19K inhibition of CED-4-dependent FLICE
activation. As CED-4 and FADD contain a CARD or a CARD-like DED,
respectively, direct interaction of E1B 19K with CARD-like domains may
be the mechanism of E1B 19K inhibition. Whereas direct interaction of
E1B 19K with CED-4 can be demonstrated, similar binding experiments
with FADD have been more difficult. Perhaps a conformational change in
FADD is required for E1B 19K binding to the DED of FADD
(32). Direct demonstration of trimolecular complex formation
between E1B 19K, CED-4, and FLICE has also been difficult to
demonstrate in vivo due to the insolubility of the E1B 19K protein
demonstrated in immunoprecipitation assays.
Comparison of the E1B 19K binding profile for Bax and CED-4 suggests
that E1B 19K binding to each is different. BH3 of E1B 19K was
sufficient to interact with both full-length Bax and CED-4 (Fig. 6B).
Also, a 29-amino-acid fragment of Bax encompassing BH3 is necessary and
sufficient to interact with E1B 19K (16). However, the E1B
19K mutant protein with amino acids 64 to 146 which did not contain BH3
but did contain the central conserved region interacted only with CED-4
and not Bax (Fig. 6B). Furthermore, the requirements for interaction
with Bax disrupted the interaction between CED-4 and E1B 19K. This
suggests that the binding sites for CED-4 and Bax on E1B 19K overlap
and that Bax binding to E1B 19K displaces CED-4 from E1B 19K (Fig. 10).
This study demonstrated that E1B 19K interacts with and inhibits
CED-4-dependent, FLICE-mediated apoptosis, suggesting that E1B 19K
requires CED-4 to block FLICE-induced apoptosis. Thus, these data
suggest that E1B 19K functions upstream of the locus of caspase
activation and regulates apoptosis by controlling caspase activation in
addition to inhibiting proapoptotic Bcl-2 family members such as Bax
and Bak. This dual mechanism of E1B 19K allows it to act as a potent
antiapoptotic protein, leading to a complete inhibition of caspase
activation and thereby apoptosis.
We thank Vishva Dixit for providing the FADD and the FLICE in
pcDNA3. We also thank A. Thomas, K. Degenhardt, A. Gaur, D. Perez, Y. Shen, A. Cuconati, R. Sundararajan, and G. Kasof for helpful comments
and suggestions.
This work was supported by a grant from the NIH (CA53370) to E.W.
| 1.
|
Boldin, M. P.,
T. M. Goncharov,
Y. V. Goltsev, and D. Wallach.
1996.
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death.
Cell
85:803-815[Medline].
|
| 2.
|
Boulakia, C. A.,
G. Chen,
F. W. H. Ng,
J. G. Teodoro,
P. E. Branton,
D. W. Nicholson,
G. G. Poirier, and G. C. Shore.
1996.
Bcl-2 and adenovirus E1B 19 kDa protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase.
Oncogene
12:529-535[Medline].
|
| 3.
|
Boyd, J.,
S. Malstrom,
T. Subramanian,
L. Venkatesh,
U. Schaeper,
B. Elangovan,
C. D'Sa-Eipper, and G. Chinnadurai.
1994.
Adenovirus E1B 19kDa and bcl-2 proteins interact with a common set of cellular proteins.
Cell
79:341-351[Medline].
|
| 4.
|
Chen, G.,
P. E. Branton,
E. Yang,
S. J. Korsmeyer, and G. C. Shore.
1996.
Adenovirus E1B 19-kDa death suppressor protein interacts with Bax but not with Bad.
J. Biol. Chem.
271:24221-24225[Abstract/Free Full Text].
|
| 5.
|
Chinnaiyan, A. M.,
D. Chaudhary,
K. O'Rourke,
E. V. Koonin, and V. M. Dixit.
1997.
Role of CED-4 in the activation of CED-3.
Nature (London)
388:728-729[Medline].
|
| 6.
|
Chinnaiyan, A. M.,
K. O'Rourke,
B. R. Lane, and V. M. Dixit.
1997.
Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death.
Science
275:1122-1126[Abstract/Free Full Text].
|
| 7.
|
Chinnaiyan, A. M.,
K. O'Rourke,
M. Tewari, and V. M. Dixit.
1995.
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.
Cell
81:505-512[Medline].
|
| 8.
|
Chinnaiyan, A. M.,
C. G. Tepper,
M. F. Seldin,
K. O'Rourke,
F. C. Kischkel,
S. Hellbardt,
P. H. Krammer,
M. E. Peter, and V. M. Dixit.
1996.
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis.
J. Biol. Chem.
271:4961-4965[Abstract/Free Full Text].
|
| 9.
|
Chiou, S.-K.,
L. Rao, and E. White.
1994.
Bcl-2 blocks p53-dependent apoptosis.
Mol. Cell. Biol.
14:2556-2563[Abstract/Free Full Text].
|
| 10.
|
Chiou, S.-K.,
C. C. Tseng,
L. Rao, and E. White.
1994.
Functional complementation of the adenovirus E1B 19K protein with Bcl-2 in the inhibition of apoptosis in infected cells.
J. Virol.
68:6553-6566[Abstract/Free Full Text].
|
| 11.
|
Chiou, S.-K., and E. White.
1997.
p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis.
J. Virol.
71:3515-3525[Abstract].
|
| 12.
|
Chittenden, T.,
C. Flemmington,
A. B. Houghton,
R. G. Ebb,
G. J. Gallo,
B. Elangovan,
G. Chinnadurai, and R. J. Lutz.
1995.
A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.
EMBO J.
14:5589-5596[Medline].
|
| 13.
|
Debbas, M., and E. White.
1993.
Wild-type p53 mediates apoptosis by E1A which is inhibited by E1B.
Genes Dev.
7:546-554[Abstract/Free Full Text].
|
| 14.
|
Ellis, H., and H. R. Horvitz.
1986.
Genetic control of programmed cell death in the nematode C. elegans.
Cell
44:817-829[Medline].
|
| 15.
|
Gooding, L. R.,
L. Aquino,
P. J. Duerksen-Hughes,
D. Day,
T. M. Horton,
S. Yei, and W. S. M. Wold.
1991.
The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells.
J. Virol.
65:3083-3094[Abstract/Free Full Text].
|
| 16.
|
Han, J.,
P. Sabbatini,
D. Perez,
L. Rao,
D. Modha, and E. White.
1996.
The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein.
Genes Dev.
10:461-477[Abstract/Free Full Text].
|
| 17.
|
Han, J.,
P. Sabbatini, and E. White.
1996.
Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K.
Mol. Cell. Biol.
16:5857-5864[Abstract].
|
| 18.
|
Hannon, G.,
D. Demetrick, and D. Beach.
1993.
Isolation of the Rb-related p130 through its interaction with cdk2 and cyclins.
Genes Dev.
7:2378-2391[Abstract/Free Full Text].
|
| 19.
|
Hashimoto, S.,
A. Ishii, and S. Yonehara.
1991.
The E1B oncogene of adenovirus confers cellular resistance to cytotoxicity of tumor necrosis factor and monoclonal anti-Fas antibody.
Int. Immunol.
3:343-351[Abstract/Free Full Text].
|
| 20.
|
Hengartner, M. O., and H. R. Horvitz.
1994.
C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2.
Cell
76:665-676[Medline].
|
| 21.
|
Hengartner, M. O., and H. R. Horvitz.
1994.
Programmed cell death in Caenorhabditis elegans.
Curr. Opin. Genet. Dev.
4:581-586[Medline].
|
| 22.
|
Hengartner, M. O.,
R. E. Ellis, and H. R. Hovitz.
1992.
Caenorhabditis elegans gene ced-9 protects cells from programmed cell death.
Nature (London)
356:494-499[Medline].
|
| 23.
|
Hu, Y.,
M. A. Benedict,
D. Wu,
N. Inohara, and G. Núñez.
1998.
Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation.
Proc. Natl. Acad. Sci. USA
95:4386-4391[Abstract/Free Full Text].
|
| 24.
|
Jacobson, M. D.,
M. Weil, and M. C. Raff.
1997.
Programmed cell death in animal development.
Cell
88:347-354[Medline].
|
| 25.
|
Kitanaka, C.,
T. Namiki,
K. Noguchi,
T. Mochizuki,
S. Kagaya,
S. Chi,
A. Hayashi,
A. Asai,
Y. Tsujimoto, and Y. Kuchino.
1997.
Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-xL on Bax-induced caspase activation and apoptosis.
Oncogene
15:1763-1672[Medline].
|
| 26.
|
Korsmeyer, S. J.
1995.
Regulators of cell death.
Trends Genet.
11:101-105[Medline].
|
| 27.
|
Li, P.,
D. Nijihawan,
I. Budihardjo,
S. M. Srinivasula,
M. Ahmad,
E. S. Alnemri, and X. Wang.
1997.
Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade.
Cell
91:479-489[Medline].
|
| 28.
|
Muchmore, S. W.,
M. Sattler,
H. Liang,
R. P. Meadows,
J. E. Harlan,
H. S. Yoon,
D. Nettesheim,
B. S. Chang,
C. B. Thompson,
S.-L. Wong,
S.-C. Ng, and S. W. Fesik.
1996.
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death.
Nature (London)
381:335-341[Medline].
|
| 29.
|
Muzio, M.,
A. M. Chinnaiyan,
F. C. Kischkel,
K. O'Rourke,
A. Shevchenko,
J. Ni,
C. Scaffidi,
J. D. Bretz,
M. Zhang,
R. Gentz,
M. Mann,
P. H. Krammer,
M. E. Peter, and V. M. Dixit.
1996.
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex.
Cell
85:817-827[Medline].
|
| 30.
|
Oltvai, Z. N.,
C. L. Millman, and S. J. Korsmeyer.
1993.
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
Cell
74:609-619[Medline].
|
| 31.
|
Pan, G.,
K. O'Rourke, and V. M. Dixit.
1998.
Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex.
J. Biol. Chem.
273:5841-5845[Abstract/Free Full Text].
|
| 32.
|
Perez, D., and E. White.
1998.
E1B 19K inhibits Fas-mediated apoptosis through FADD-dependent sequestration of FLICE.
J. Cell Biol.
141:1255-1266[Abstract/Free Full Text].
|
| 33.
|
Rao, L.,
M. Debbas,
P. Sabbatini,
D. Hockenberry,
S. Korsmeyer, and E. White.
1992.
The adenovirus E1A proteins induce apoptosis which is inhibited by the E1B 19K and Bcl-2 proteins.
Proc. Natl. Acad. Sci. USA
89:7742-7746[Abstract/Free Full Text].
|
| 34.
|
Rao, L.,
D. Modha, and E. White.
1997.
The E1B 19K protein associates with lamins in vivo and its proper localization is required for inhibition of apoptosis.
Oncogene
15:1587-1597[Medline].
|
| 35.
|
Rao, L.,
D. Perez, and E. White.
1996.
Lamin proteolysis facilitates nuclear events during apoptosis.
J. Cell Biol.
135:1441-1455[Abstract/Free Full Text].
|
| 36.
|
Rao, L., and E. White.
1997.
Bcl-2 and ICE family of apoptotic regulators: making a connection.
Curr. Opin. Genet. Dev.
7:52-58[Medline].
|
| 37.
|
Renvoize, C.,
R. Roger,
N. Moulian,
J. Bertoglio, and J. Breard.
1997.
Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis.
J. Immunol.
159:126-134[Abstract].
|
| 38.
|
Sabbatini, P.,
J. Lin,
A. J. Levine, and E. White.
1995.
Essential role for p53-mediated transcription in apoptosis but not growth suppression.
Genes Dev.
9:2184-2192[Abstract/Free Full Text].
|
| 39.
|
Sattler, M.,
H. Liang,
D. Nettesheim,
R. P. Meadows,
J. E. Harlan,
M. Eberstadt,
H. S. Yoon,
S. B. Shuker,
B. S. Chang,
A. J. Minn,
C. B. Thompson, and S. W. Fesik.
1997.
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Science
275:983-986[Abstract/Free Full Text].
|
| 40.
|
Schott, A. F.,
I. J. Apel,
G. Nuñez, and M. F. Clarke.
1995.
Bcl-XL protects cancer cells from p53-mediated apoptosis.
Oncogene
11:1389-1394[Medline].
|
| 41.
|
Seshagiri, S., and L. K. Miller.
1997.
Caenorhabditis elegans CED-4 stimulates CED-3 processing and CED-3-induced apoptosis.
Curr. Biol.
7:455-460[Medline].
|
| 42.
|
Shaham, S., and H. R. Horvitz.
1996.
Developing Caenorhabditis elegans neurons may contain both cell-death protective and killer activities.
Genes Dev.
10:578-591[Abstract/Free Full Text].
|
| 43.
|
Simonian, P. L.,
D. A. M. Grillot,
R. Merino, and G. Nuñez.
1996.
Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL.
J. Biol. Chem.
271:22764-22772[Abstract/Free Full Text].
|
| 44.
|
Spector, M. S.,
S. Desnoyers,
D. J. Hoeppner, and M. O. Hengartner.
1997.
Interaction between the C. elegans cell-death regulators CED-9 and CED-4.
Nature (London)
385:653-656[Medline].
|
| 45.
|
Tarodi, B.,
T. Subramanian, and G. Chinnadurai.
1993.
Functional similarity between adenovirus E1B 19K gene and Bcl-2 oncogene: mutant complementation and suppression of cell death induced by DNA damaging agents.
Int. J. Oncol.
3:467-472.
|
| 46.
|
White, E.
1996.
Life, death, and the pursuit of apoptosis.
Genes Dev.
10:1-15[Free Full Text].
|
| 47.
|
White, E.,
S. H. Blose, and B. Stillman.
1984.
Nuclear envelope localization of an adenovirus tumor antigen maintains the integrity of cellular DNA.
Mol. Cell. Biol.
4:2865-2875[Abstract/Free Full Text].
|
| 48.
|
White, E., and R. Cipriani.
1990.
Role of adenovirus E1B proteins in transformation: altered organization of intermediate filaments in transformed cells that express the 19-kilodalton protein.
Mol. Cell. Biol.
10:120-130[Abstract/Free Full Text].
|
| 49.
|
White, E., and R. Cipriani.
1989.
Specific disruption of intermediate filaments and the nuclear lamina by the 19-kDa product of the adenovirus E1B oncogene.
Proc. Natl. Acad. Sci. USA
86:9886-9890[Abstract/Free Full Text].
|
| 50.
|
White, E.,
P. Sabbatini,
M. Debbas,
W. S. M. Wold,
D. I. Kusher, and L. Gooding.
1992.
The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor .
Mol. Cell. Biol.
12:2570-2580[Abstract/Free Full Text].
|
| 51.
|
Wu, D.,
H. D. Wallen,
N. Inohara, and G. Nuñez.
1997.
Interaction and regulation of the Caenorhabditis elegans death protease CED-3 by CED-4 and CED-9.
J. Biol. Chem.
272:21449-21454[Abstract/Free Full Text].
|
| 52.
|
Wu, D.,
H. D. Wallen, and G. Nuñez.
1997.
Interaction and regulation of subcellular localization of CED-4 by CED-9.
Science
275:1126-1128[Abstract/Free Full Text].
|
| 53.
|
Yin, X.-M.,
|